v3.26.1
Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Mar. 06, 2026
Aug. 01, 2025
Jul. 30, 2025
Mar. 08, 2024
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 23, 2025
Sep. 15, 2025
Mar. 20, 2025
Nov. 16, 2024
Product Information [Line Items]                        
Cash and investment securities         $ 6,600,000   $ 8,600,000          
Revenue from contract with customer excluding         1,110,956 $ 393,572            
Allowance for credit losses         0   0          
Provision for income taxes         0              
Unrecognized tax benefits         0              
Deferred tax assets         $ 19,300,000   $ 19,000,000.0          
Deferred tax assets valuation allowance coverage percent         100.00%   100.00%          
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount         6,127,697 6,401,581            
Unvested Restricted Stock Units [Member]                        
Product Information [Line Items]                        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount         189,682 96,984            
Common Stock [Member]                        
Product Information [Line Items]                        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount         5,635,415 6,304,597            
Warrant [Member]                        
Product Information [Line Items]                        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount         302,600              
Four Customers [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]                        
Product Information [Line Items]                        
Revenue from contract with customer excluding         $ 960,367 $ 350,448            
Concentration risk, percentage         86.30% 89.00%            
Two Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]                        
Product Information [Line Items]                        
Revenue from contract with customer excluding         $ 803,575   $ 916,953          
Concentration risk, percentage         80.60%   84.10%          
One Customer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Non-US [Member]                        
Product Information [Line Items]                        
Revenue from contract with customer excluding         $ 234,397 $ 48,333            
Concentration risk, percentage         21.10% 65.80%            
Two Customer [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] | Non-US [Member]                        
Product Information [Line Items]                        
Revenue from contract with customer excluding         $ 772,668   $ 916,953          
Concentration risk, percentage         77.50%   84.10%          
Two CROs [Member] | Contract Research Organizations [Member] | Supplier Concentration Risk [Member]                        
Product Information [Line Items]                        
Concentration risk, percentage         63.40% 77.90%            
Research services purchased         $ 651,703 $ 483,426            
Two CROs [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]                        
Product Information [Line Items]                        
Concentration risk, percentage         71.00%   67.00%          
Accounts payable         $ 752,682   $ 571,149          
Sales Agreement [Member]                        
Product Information [Line Items]                        
Maximum aggregate offering price $ 4,238,000                      
Commission Rate 3.00%                      
Gates Foundation [Member]                        
Product Information [Line Items]                        
Proceeds from grants                       $ 3,092,000
Revenue from contract with customer excluding         $ 252,969              
Fondazione Biotecnopolo Di Siena Fbs [Member]                        
Product Information [Line Items]                        
Proceeds from grants                     $ 4,500,000  
Grants Receivable                     $ 2,432,756  
December Two Thousand Twenty Five Amendment [Member]                        
Product Information [Line Items]                        
Debt instrument convertible conversion price                 $ 1.05      
Mr Mark A Emalfarb [Member]                        
Product Information [Line Items]                        
Principal amount                   $ 1,000,000    
Common Stock [Member]                        
Product Information [Line Items]                        
Issuance of common stock upon settlement of convertible debt               $ 910,000        
Conversion of convertible notes, shares               556,623        
Shares issued   6,052,000                    
Public offering price, per share   $ 0.95 $ 0.95                  
Proceeds from issuance initial public offering     $ 4,900,000                  
Senior Secured Convertible Promissory Notes [Member]                        
Product Information [Line Items]                        
Principal amount       $ 6,000,000                
Interest rate       8.00%                
Proceeds from Issuance of Senior Long-Term Debt       $ 5,824,326